Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Estrone sulfatase activity in patients with advanced ovarian cancer.

Chura JC, Blomquist CH, Ryu HS, Argenta PA.

Gynecol Oncol. 2009 Jan;112(1):205-9. doi: 10.1016/j.ygyno.2008.08.037. Epub 2008 Oct 22.

PMID:
18947862
2.

Steroid-converting enzymes in human ovarian carcinomas.

Chura JC, Ryu HS, Simard M, Poirier D, Tremblay Y, Brooker DC, Blomquist CH, Argenta PA.

Mol Cell Endocrinol. 2009 Mar 25;301(1-2):51-8. doi: 10.1016/j.mce.2008.07.015. Epub 2008 Aug 3.

PMID:
18723074
3.

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.

Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, Gold MA.

Gynecol Oncol. 2009 Feb;112(2):337-41. doi: 10.1016/j.ygyno.2008.10.009. Epub 2008 Nov 28.

PMID:
19041126
4.

A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.

Secord AA, Havrilesky LJ, O'Malley DM, Bae-Jump V, Fleming ND, Broadwater G, Cohn DE, Gehrig PA.

Gynecol Oncol. 2009 Sep;114(3):442-7. doi: 10.1016/j.ygyno.2009.06.005. Epub 2009 Jun 26.

PMID:
19560193
5.

Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.

Aletti GD, Podratz KC, Cliby WA, Gostout BS.

Gynecol Oncol. 2009 Jan;112(1):22-7. doi: 10.1016/j.ygyno.2008.09.010. Epub 2008 Oct 23.

PMID:
18947860
6.

Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.

Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM.

Gynecol Oncol. 2007 Jun;105(3):625-9. Epub 2007 Feb 22.

PMID:
17320156
7.

GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer.

Kolwijck E, Zusterzeel PL, Roelofs HM, Hendriks JC, Peters WH, Massuger LF.

Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2176-81. doi: 10.1158/1055-9965.EPI-09-0098.

8.

[Local production of estrogen via aromatase and estrone sulfatase in breast cancer tissue].

Utsumi T.

Nihon Geka Gakkai Zasshi. 1989 Jun;90(6):920-7. Japanese.

PMID:
2796962
9.

Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.

Mustea A, Pirvulescu C, Könsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J.

Cytokine. 2008 Apr;42(1):77-84. doi: 10.1016/j.cyto.2008.01.011. Epub 2008 Mar 7.

PMID:
18329282
10.

The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).

Cheng X, Jiang R, Li ZT, Tang J, Cai SM, Zhang ZY, Tian WJ, Zang RY.

Eur J Surg Oncol. 2009 Oct;35(10):1105-8. doi: 10.1016/j.ejso.2009.03.010. Epub 2009 May 13.

PMID:
19443175
11.

Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer.

Bakkum-Gamez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL, O'Malley DM, Cliby WA.

Obstet Gynecol. 2009 Jan;113(1):11-7. doi: 10.1097/AOG.0b013e3181917a0c.

PMID:
19104354
12.

A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?

Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL.

Gynecol Oncol. 2002 Jan;84(1):36-42.

PMID:
11748973
13.

Relapse and survival in early-stage ovarian cancer.

Lenhard SM, Bufe A, Kümper C, Stieber P, Mayr D, Hertlein L, Kirschenhofer A, Friese K, Burges A.

Arch Gynecol Obstet. 2009 Jul;280(1):71-7. doi: 10.1007/s00404-008-0877-z. Epub 2008 Dec 18.

PMID:
19093129
14.

Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer.

Eisenkop SM, Spirtos NM, Lin WC.

Gynecol Oncol. 2006 Feb;100(2):344-8. Epub 2005 Oct 3.

PMID:
16202446
15.

Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR.

Gynecol Oncol. 2009 Jul;114(1):26-31. doi: 10.1016/j.ygyno.2009.03.018. Epub 2009 Apr 23.

PMID:
19395008
16.

Clinical features and outcomes of uterine and ovarian carcinosarcoma.

Jonson AL, Bliss RL, Truskinovsky A, Judson P, Argenta P, Carson L, Dusenbery K, Downs LS Jr.

Gynecol Oncol. 2006 Mar;100(3):561-4. Epub 2005 Nov 4.

PMID:
16271748
17.

Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer.

Aletti GD, Podratz KC, Jones MB, Cliby WA.

J Am Coll Surg. 2006 Oct;203(4):521-6. Epub 2006 Aug 23.

PMID:
17000396
18.

Immunohistologic localization of estrone sulfatase in uterine endometrium and adenomyosis.

Ezaki K, Motoyama H, Sasaki H.

Obstet Gynecol. 2001 Nov;98(5 Pt 1):815-9.

PMID:
11704174
19.

Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.

Wang L, Madigan MC, Chen H, Liu F, Patterson KI, Beretov J, O'Brien PM, Li Y.

Gynecol Oncol. 2009 Aug;114(2):265-72. doi: 10.1016/j.ygyno.2009.04.031. Epub 2009 May 17.

PMID:
19450871
20.

Steroid sulfatase and 17 beta-hydroxysteroid oxidoreductase activities in mouse tissues.

Milewich L, Garcia RL, Gerrity LW.

J Steroid Biochem. 1984 Nov;21(5):529-38.

PMID:
6239954

Supplemental Content

Support Center